Filtered By:
Infectious Disease: Pandemics
Management: WHO
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 113 results found since Jan 2013.
Grace Under Pressure: Resiliency of Quality Monitoring of Stroke Care During the Covid-19 Pandemic in Mexico City
Stroke is one of the leading causes of death and disability among adults worldwide. The World Health Organization (WHO) officially declared a COVID-19 pandemic on March 11, 2020. The first case in Mexico was confirmed in February 2020, subsequently becoming one of the countries most affected by the pandemic. In 2020, The National Institute of Neurology of Mexico started a Quality assurance program for stroke care, consisting of registering, monitoring and feedback of stroke quality measures through the RES-Q platform. We aim to describe changes in the demand for stroke healthcare assistance at the National Institute of Neu...
Source: Frontiers in Neurology - April 6, 2022 Category: Neurology Source Type: research
Nearly Everyone in the World is Breathing Polluted Air, Says WHO
(GENEVA, Switzerland) — The U.N. health agency says nearly everybody in the world breathes air that doesn’t meet its standards for air quality, calling for more action to reduce fossil-fuel use, which generates pollutants that cause respiratory and blood-flow problems and lead to millions of preventable deaths each year.
The World Health Organization, about six months after tightening its guidelines on air quality, on Monday issued an update to its database on air quality that draws on information from a growing number of cities, towns, and villages across the globe — now totaling over 6,000 municipalitie...
Source: TIME: Health - April 4, 2022 Category: Consumer Health News Authors: JAMEY KEATEN / AP Tags: Uncategorized climate change Climate Is Everything Environment healthscienceclimate wire Source Type: news
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports
CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.PMID:34919240 | DOI:10.26355/eurrev_202112_27435
Source: Pharmacological Reviews - December 17, 2021 Category: Drugs & Pharmacology Authors: S Lee J W Yang S Y Jung M S Kim D K Yon S W Lee H-C Kang E Dragioti K Tizaoui L Jacob A Koyanagi J-E Salem K Kostev A Lascu J I Shin J H Kim L Smith Source Type: research
